. 2022 Sep 2;12(6):1921–1935. doi: 10.3233/JPD-223201

Table 3.

Overview of the demographic, clinical and imaging data at baseline and follow-up of the three subgroups

Demographic data	Baseline (Bl)			Follow-up (Fu)			Statistical Analysis p < 0.017
	1:	2:	3:	1:	2:	3:	Bl vs. Fu			1 vs. 2		1 vs. 3		2 vs. 3
	MIBG^N	MIBG^P	MIBG^P	MIBG^N	MIBG^P	MIBG^P	p			p		p		p
	FP-CIT^N	FP-CIT^N	FP-CIT^P	FP-CIT^N	FP-CIT^N	FP-CIT^P
	n = 8	n = 9	n = 20	n = 8	n = 9	n = 18
							1	2	3	Bl	Fu	Bl	Fu	Bl	Fu
Male (%)	6 (75.0)	8 (88.9)	18 (90)	6 (75.0)	8 (88.9)	16 (88.9)
Age at diagnosis (y)	58.5 (53.8–65.0)	66.0 (57.5–71.0)	65.0 (61.0–68.5)							0.078		0.047		n.s.
Age (y)	58.5 (53.8–65.0)	66.0 (57.5–71.0)	66.0 (62.3–70.5)	61.5 (60.3–68.3)	69.0 (61.0–77.0)	70.5 (67.8–74.0)				0.070	n.s.	0.016	0.012	n.s.	n.s.
Fu time (mo)	46.5 (22.5–72.8)	48.0 (33.0–63.0)	48.5 (36.0–62.3)							n.s.		n.s.		n.s.
RBD Duration at diagnosis (mo)	57.0 (12.5–113.3)	55.0 (29.5–151.0)	60.0 (24.8–71.3)							n.s.		n.s.		n.s.
ADT (%)	5 (62.5)	2 (22.2)	5 (25.0)	5 (62.5)	2 (22.2)	4 (22.2)
UPDRS-III	3 (0–6)	2 (1–3)	1 (0–4)	3 (1–3)	3 (1–3)	5 (2–5)	n.s.^*	n.s.^*	0.001^*	n.s.	n.s.	n.s.	0.041	n.s.	0.009
TDI	28.6 (21.3–33.7)	16.0 (5.5–21.9)	17.4 (10.5–22.3)	30.1 (27.8–32.4)	12.0 (6.0–13.8)	14.0 (10.3–21.3)	n.s.^*	0.074^*	0.022^*	0.004	< 0.0001	0.001	< 0.0001	n.s.	n.s.
(T) score	6.0 (3.8–7.4)	1.5 (0.0–5.5)	2.4 (0.0–5.0)	5.5 (4.5 –7.3)	0.0 (0.0–1.5)	1.5 (0.0.–2.3)	n.s.^*	0.063^*	0.009^*	0.046	0.003	0.008	< 0.0001	n.s.	n.s.
(D) score	11.0 (8.0–13.5)	7.0 (3.0–9.0)	9.0 (6.3–10.8)	11.5 (10.0–13.0)	5.5 (1.3–7.8)	8.0 (4.0–9.0)	n.s.^*	n.s.^*	0.029^*	0.018	0.001	0.083	< 0.001	n.s.	n.s.
(I) score	11.5 (9.5–13.0)	4.0 (2.5–9.0)	5.5 (3.0–8.8)	13.0 (12.3–13.8)	5.0 (3.5–7.8)	6.0 (3.0–9.0)	n.s.^*	n.s.^*	n.s.^*	0.007	< 0.001	0.001	< 0.0001	n.s.	n.s.
MOCA	26.5 (24.3–28.5)	26.0 (24.0–28.5)	27.0 (26.0–28.8)	28.5 (27.0–29.8)	28.0 (27.0–29.0)	28.0 (27.0–29.0)	n.s.	0.094	n.s.	n.s.	n.s.	n.s.	0.685	n.s.	n.s.
PDNMS	10.0 (6.0–13.8)	6.0 (4.0–8.0)	7.0 (4.0–8.0)	8.5 (4.8–15.5)	10.0 (6.0–14.5)	8.0 (4.8–10.0)	n.s.	0.047	0.035	n.s.	n.s.	0.019	n.s.	n.s.	n.s.
PD conv (%)				0 (0)	0 (0)	7 (38.9)
Results of [¹²³I]MIBG scintigraphy and [¹²³I]FP-CIT-SPECT
[¹²³I]MIBG value	1.7 (1.6–1.9)	1.2 (1.1–1.3)	1.1 (1.1–1.2)								< 0.001		< 0.0001		0.077
lowest caudatal value	2.8 (2.5–2.9)	2.2 (2.0–2.8)	1.9 (1.5–2.2)								0.097		< 0.0001		0.031
lowest putaminal value	2.4 (2.2–2.5)	2.0 (1.8–2.4)	1.5 (1.2–1.8)								0.145		< 0.00001		< 0.001

All values are shown as median (IQR). Non-parametric Mann-Whitney-U-test was used to compare subgroups. Wilcoxon-test was used to compare baseline and follow-up results within each group. ^*If the question was one-sided, the medians were compared. If the observed tendency corresponded to the null hypothesis, the test was evaluated as not significant. ADT, antidepressant pharmacological therapy. (T) threshold. (D) discrimination. (I) identification. Conv, converter.